Diagnos (ADK.V) has gained some serious momentum in the last few months. The company uses algorithms to screen diabetic patients to determine the presence of retinopathy. Typically, retinopathy is hard to diagnose, and if unattended can lead to blindness. By leveraging their flagship product CARA (Computer Assisted Retinal Analysis), a screening test can be administered in the absence of a medical specialist and used to determine the propensity for presence of the condition. If the test is positive, this patient can then be referred to a medical specialist.
In addition to having one of the world leading experts on its board (Dr. Netan Choudhry), ADK.V has already signed with Bayer and Novartis for pilot projects, the most recent one will take place in Toronto.
The company has also launched multiple pilot projects around the world -- in Mexico, South Asia, and North Africa.
DISCLAIMER: The work included in this article is based on current events, technical charts, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The content of rally is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions - rally cannot take responsibility for your investment decisions.
